- Policy
- DAA Daklinza and Sunvepra to be pulled out from Korea
- by Lee, Tak-Sun Jun 17, 2020 06:21am
- ‘Daklinza plus Sunvepra,’ the first direct acting antivirals (DAA) in Korea praised to have opened the era of ‘curable hepatitis C,’ would be withdrawn from the Korean market after five years since the launch. Bristol Myers Squibb (BMS) Korea, a supplier of the drug in Korea, has recently reported Ministry of Food and Drug Safety (MFD
- Company
- Takeda's partners relieved their worries
- by An, Kyung-Jin Jun 17, 2020 06:20am
- Domestic partner companies are nervous as Takeda officially sells its business units. As Celltrion decided to maintain a co-sales contract for 18 items that take over copyrights, immediate changes were avoided, but it may be difficult to maintain copyrights after changing partners. According to the industry on the 15th, Celltrion is expec
- Company
- Korean drug trade in May makes first surplus amid COVID-19
- by Kim, Jin-Gu Jun 16, 2020 06:20am
- In May, the Korean pharmaceutical export volume has hit the historic high. It also was the first month to make pharmaceutical trade surplus in Korea. Europe, where the COVID-19 started spreading later than in Korea, had a sharp surge of demand on essential drug that boosted the drug trade in Korea. ◆New historic high trade volume in t
- Company
- Antidiabetic Suganon readies clinical trial for CAVD
- by Nho, Byung Chul Jun 16, 2020 06:20am
- Diabetes treatment Suganon (evogliptin) has started a clinical trial to receive an indication to treat calcific aortic valve disease (CAVD). In North America, the number of CAVD patients is projected at 1.50 million to 11.5 million (prevalence rate ranging from 2.5 percent to 25 percent in age group over 65), and the related prosthetic
- Policy
- Phase III trial of Eylea biosimilar is ready to kick off
- by Lee, Tak-Sun Jun 16, 2020 06:20am
- Samsung Bioepis is accelerating the development of a macular degeneration treatment, Eylea biosimilar (Aflibercept, Bayer Korea). The development stage is the most advanced in Korea. On the 11th, the MFDS approved phase III global clinical trials for Eylea biosimilar ‘SB15’ by Samsung Bioepis It is phase III trial comparing the ef
- Company
- Takeda to sell 18 items of diabetes & OTC to Celltrion
- by Eo, Yun-Ho Jun 16, 2020 06:19am
- The sale of some items of diabetes and OTC by Takeda was confirmed. Celltrion is the company that acquires these items. Recently, the headquarters of Takeda trademarks, for patents, trademarks, and rights to sell 18 non-core generic and OTC sold in nine countries, including Korea, Thailand, Taiwan, Hong Kong, Macau, Philippines, Singapore,
- Company
- Newly approved JAK inhibitor Rinvoq to apply for reimburseme
- by Eo, Yun-Ho Jun 15, 2020 06:17am
- The fourth Janus kinase (JAK) inhibitor in Korea Rinvoq is swiftly pursuing the healthcare reimbursement listing. According to the pharmaceutical industry sources, AbbVie Korea submitted the healthcare reimbursement application for Rinvoq (upadacitinib) on June 4, immediately after receiving the market approval. Considering Pfizer’
- Company
- Takeda Korea, announces massive ERP
- by An, Kyung-Jin Jun 15, 2020 06:16am
- The aftermath for the sale of the Takeda’s business division began. According to the industry on the 12th, Takeda Korea held a town hall meeting for all employees this morning, and had a time to share information related to the sale of the business division. This is a follow-up procedure following the formalization of a contract to sell
- Company
- The KDPU joined the memorial against racism
- by An, Kyung-Jin Jun 15, 2020 06:16am
- The domestic pharmaceutical industry gathered to honor memory of George Floyd, a black man who died from the abuse of public power by the American police. On the afternoon of the 11th, Lundbeck Korea branch of the Koea Democratic Pharmaceutical Union held a memorial performance for George Floyd during a protest rally in front of the Lundb
- Policy
- 18 Champix IMD suspected of selling before patent expiration
- by Lee, Tak-Sun Jun 15, 2020 06:16am
- 18 incrementally modified drugs (IMDs) of Champix (varenicline) are undergoing administrative measure for selling the products before the original’s patent was expired. Some of their item approvals have been revoked by the related administrative measure. Before the Champix’ patent expires next month, the follow-on drug market would flu
